Table of Contents  

Additional and prolonged anticoagulation in patients with acute coronary syndrome? The ATLAS ACS 2-TIMI 51 trial

Alexander Niessner
Published in : HAMDAN MEDICAL JOURNAL ; Vol 5, No 2 (2012)
DOI : 10.7707/hmj.v5i2.172

Abstract


The additional application of low-dose rivaroxaban twice daily to standard therapy showed improved efficacy in patients with acute coronary syndrome (ACS) in the ATLAS ACS 2-TIMI 51 (anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome thrombolysis in myocardial infarction) study. All-cause mortality was even reduced with 2 Å~ 2.5 mg rivaroxaban. However, increased efficacy was associated with worse safety with, most importantly, an increased rate of intracranial bleeding.



View article in  :   PDF     HTML    



Add comment 





Home  Editorial Board  Search  Current Issue  Archive Issues  Announcements  Aims & Scope  About the Journal  How to Submit  Contact Us
Find out how to become a part of the HMJ  |   CLICK HERE >>
© Copyright 2012 - 2013 HMJ - HAMDAN Medical Journal. All Rights Reserved         Website Developed By Cedar Solutions INDIA